Last reviewed · How we verify
NCT03678454
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
trial in Chronic Myeloid Leukemia in 80 participants. Completed in 31 March 2022.
31 March 2022
Quick facts
| Lead sponsor | Incyte Biosciences Benelux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 3 February 2017 |
| Primary completion | 31 March 2022 |
| Estimated completion | 31 March 2022 |
| Sites | 19 locations across Belgium |
Conditions studied
- Chronic Myeloid Leukemia — all drugs for Chronic Myeloid Leukemia →
- CML — all drugs for CML →
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia — all drugs for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia →
- Ph+ ALL — all drugs for Ph+ ALL →
Sponsor
Incyte Biosciences Benelux
Who can join
18 and older, any sex, with Chronic Myeloid Leukemia or CML. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Tan FH, Putoczki TL, Stylli SS, Luwor RB. · · 2019 · cited 142× · PMID 30705592 · DOI 10.2147/ott.s189391 -
Advances in targeted therapy for acute myeloid leukemia.
Yu J, Jiang PYZ, Sun H, Zhang X, et al · · 2020 · cited 48× · PMID 32477567 · DOI 10.1186/s40364-020-00196-2 -
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T, Havelange V, Theunissen K, Meers S, et al · · 2021 · cited 18× · PMID 33942128 · DOI 10.1007/s00277-021-04507-x -
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.
Devos T, Deeren D, Theunissen K, Selleslag D, et al · · 2025 · cited 1× · PMID 40811042 · DOI 10.1080/16078454.2025.2534196 -
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registry
Devos T, Deeren D, Theunissen K, Selleslag D, et al · · 2024 · DOI 10.21203/rs.3.rs-3973387/v1 -
Abstract Book for the 27th Congress of the European Hematology Association
· 2022
Verify or expand the search:
- PubMed search for NCT03678454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myeloid Leukemia
Currently open trials in the same condition.
- NCT06817720 — Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni · Phase 2 · recruiting
- NCT07238712 — Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies · Phase 2 · recruiting
- NCT06453902 — TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients · Phase 2 · recruiting
- NCT06390306 — The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP · recruiting
- NCT06355583 — Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03678454 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Incyte Biosciences Benelux
- Last refreshed: 12 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03678454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing